Contineum Net Interest Income from 2010 to 2026
| CTNM Stock | 14.48 0.32 2.16% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 10.2 M | Current Value 10.8 M | Quarterly Volatility 4 M |
Check Contineum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Contineum Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 10.8 M, Interest Income of 10.8 M or Depreciation And Amortization of 221.4 K, as well as many indicators such as Price To Sales Ratio of 6.23, Dividend Yield of 0.0 or PTB Ratio of 3.26. Contineum financial statements analysis is a perfect complement when working with Contineum Therapeutics Valuation or Volatility modules.
Contineum | Net Interest Income | Build AI portfolio with Contineum Stock |
Evaluating Contineum Therapeutics's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Contineum Therapeutics Class's fundamental strength.
Latest Contineum Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Contineum Therapeutics Class over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Contineum Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Contineum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Contineum Net Interest Income Regression Statistics
| Arithmetic Mean | 1,859,385 | |
| Geometric Mean | 588,440 | |
| Coefficient Of Variation | 217.33 | |
| Mean Deviation | 3,159,882 | |
| Median | (255,000) | |
| Standard Deviation | 4,041,055 | |
| Sample Variance | 16.3T | |
| Range | 11M | |
| R-Value | 0.74 | |
| Mean Square Error | 7.8T | |
| R-Squared | 0.55 | |
| Significance | 0.0006 | |
| Slope | 593,798 | |
| Total Sum of Squares | 261.3T |
Contineum Net Interest Income History
About Contineum Therapeutics Financial Statements
Contineum Therapeutics investors utilize fundamental indicators, such as Net Interest Income, to predict how Contineum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 10.2 M | 10.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Contineum Therapeutics Correlation against competitors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.